Arbutus Biopharma Corporation Stock News

One thing we could say about the analysts on Arbutus Biopharma Corporation (NASDAQ:ABUS) - they aren't optimistic...

Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric o

Arlington Asset Investment (NYSE:AI) -21% after suspending Q1 dividend.BGC Partners (NASDAQ:BGCP) -20% on dividend cut.Altimmune (NASDAQ:ALT) -15% on FY earnings.Arbutus Biopharma (NASDAQ:ABUS)�

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $6.00. The company's shares closed

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a

Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting

Arbutus Biopharma Corporation (ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy su

After years of research, technology for silencing a gene---stopping it from producing a disease-causing protein---has reached patients. AstraZeneca is now

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS) on March 13 and set a price target of $6.00. The company's shares

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) on March 13 and

ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup.Alector (NASDAQ:ALEC) initiated with Buy rating and $40 (36% upside) price target at Citi.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In

Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV).

Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad

WARMINSTER, Pa., Feb. 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.